EGFR and cancer: Not only have EGFR-mutant tumors demonstrated increased VEGF dependence compared to EGFR-wildtype tumors, but VEGF inhibitors have also demonstrated the ability to enhance antitumor activity in EGFR T790M positive cancer cells [7–10].